RxDoctor Payments Data

Judith Hackett, MD

Family Medicine · New Orleans, LANPI 1487610598

Payments from drug & device makers

$1,432in general payments, 2019–2025

Across 51 payments — averaging $28.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$504
  • AbbVie$221
  • GSK$142
  • Acadia Pharmaceuticals Inc$113
  • Gilead$111
  • Teva Pharmaceuticals USA, Inc.$100
  • plus $241 from 6 others

What the payments were for

  • Food & beverage$1,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,432 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$7,371
Medicare patients
24
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$84,751
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl83$21,428
MounjaroTirzepatide17$18,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,312
UbrelvyUbrogepant11$12,864
SymbicortBudesonide/Formoterol Fumarate49$12,168
MyrbetriqMirabegron11$4,816
Lidocaine16$4,038
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine92$2,594
Albuterol Sulfate HfaAlbuterol Sulfate105$2,370
Promethazine Hcl154$2,037
Gabapentin153$1,734
Cyproheptadine Hcl87$1,606
Mometasone Furoate11$1,571
Tramadol Hcl273$1,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$77$18,14217 claims
GSKTrelegy Ellipta$142$14,31219 claims
AbbVieUbrelvy$221$12,86411 claims
AstraZenecaSymbicort$504$12,16849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →